Filtered By:
Source: Neurology
Condition: Chronic Pain
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 17 results found since Jan 2013.
Cystatin C as a Marker of Degeneration in Multiple Sclerosis (P03.241)
CONCLUSIONS: Cystatin C concentration decrease in RR form of MS could give evidence for high disease activity in this stage of the disease with high myelin damage and neurodegeneration.Supported by: Grant IGA MHCZ NT 12221-5/2010.Disclosure: Dr. Prikrylová Vranová has nothing to disclose. Dr. Sládková has nothing to disclose. Dr. Mares has nothing to disclose. Dr. Hlustík has nothing to disclose. Dr. Langová has nothing to disclose. Dr. Kanovsky has nothing to disclose.
Source: Neurology - February 14, 2013 Category: Neurology Authors: Prikrylova Vranova, H., Sladkova, V., Mares, J., Hlustik, P., Langova, J., Kanovsky, P. Tags: P03 Multiple Sclerosis: Disease Biomarkers Source Type: research
Toward an epidemiology of poststroke spasticity
Poststroke spasticity (PSS)-related disability is emerging as a significant health issue for stroke survivors. There is a need for predictors and early identification of PSS in order to minimize complications and maladaptation from spasticity. Reviewing the literature on stroke and upper motor neuron syndrome, spasticity, contracture, and increased muscle tone measured with the Modified Ashworth Scale and the Tone Assessment Scale provided data on the dynamic time course of PSS. Prevalence estimates of PSS were highly variable, ranging from 4% to 42.6%, with the prevalence of disabling spasticity ranging from 2% to 13%. Da...
Source: Neurology - January 14, 2013 Category: Neurology Authors: Wissel, J., Manack, A., Brainin, M. Tags: ARTICLE Source Type: research
